# OnCo record surrogate-validation (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/surrogate-validation/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "surrogate-validation" ;
  schema:name "Surrogate endpoint validation: which stand-ins have earned trust"@en ;
  schema:alternateName "surrogate validation"@en, "validated surrogate endpoint"@en, "validation of surrogate endpoints"@en, "surrogate threshold effect"@en, "trial-level correlation"@en, "trial-level association"@en, "patient-level correlation"@en, "individual-level surrogacy"@en, "meta-analytic validation"@en, "meta-analysis of surrogacy"@en, "reasonably likely surrogate"@en, "reasonably likely to predict"@en, "accepted surrogate"@en, "surrogate for overall survival"@en, "surrogate for OS"@en, "does not correlate with survival"@en, "did not translate into survival"@en, "PFS-OS correlation"@en, "pCR-EFS correlation"@en, "MRD as an endpoint"@en, "MRD negativity as endpoint"@en, "stage shift without mortality benefit"@en, "FDA table of surrogate endpoints"@en ;
  schema:description "A surrogate endpoint only deserves trust if trials have shown that moving it moves the outcome that matters, in that disease and for that kind of drug; some stand-ins have passed that test, several have not, and the record differs endpoint by endpoint."@en ;
  schema:url <https://onco.cc/terms/surrogate-validation/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Surrogate_endpoint> ;
  schema:citation <https://en.wikipedia.org/wiki/Surrogate_endpoint>, <https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics> ;
  onco:related <https://onco.cc/terms/surrogate-endpoint/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/recist/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/confirmatory-trial/>, <https://onco.cc/terms/crossover/>, <https://onco.cc/terms/trial-failure-modes/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/tropion-breast01/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/monarche/>, <https://onco.cc/trials/natalee/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/perseus/>, <https://onco.cc/trials/captivate/>, <https://onco.cc/trials/announce/>, <https://onco.cc/trials/atlantis/>, <https://onco.cc/trials/ukctocs/>, <https://onco.cc/trials/imvigor011/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/> .